Claims for Patent: 7,820,788

Summary for Patent: 7,820,788

Title:	Compositions and methods of delivery of pharmacological agents
Abstract:	The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
Inventor(s):	Desai; Neil P. (Los Angeles, CA), Soon-Shiong; Patrick (Los Angeles, CA), Trieu; Vuong (Calabasas, CA)
Assignee:	Abraxis Bioscience, LLC (Los Angeles, CA)
Application Number:	11/553,339
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,820,788
Patent Claims:	1. A pharmaceutical composition for injection comprising paclitaxel and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises albumin, wherein the albumin and the paclitaxel in the composition are formulated as particles, wherein the particles have a particle size of less than about 200 nm, and wherein the weight ratio of albumin to paclitaxel in the composition is about 1:1 to about 9:1. 2. The pharmaceutical composition of claim 1, wherein the albumin is human serum albumin. 3. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is free of Cremophor. 4. A method of treating a disease comprising administering an effective amount of a pharmaceutical composition of claim 1, wherein the disease is cancer, arthritis, or restenosis. 5. The method of claim 4, wherein the disease is cancer. 6. The method of claim 4, wherein the disease is arthritis. 7. The method of claim 4, wherein the disease is restenosis. 8. The method of claim 4, wherein the composition is administered intravenously, intraarterially, intrapulmonarily, orally, by inhalation, intravesicularly, intramuscularly, intra-tracheally, subcutaneously, intraocularly, intrathecally, or transdermally. 9. The method of claim 8, wherein the pharmaceutical composition is administered intravenously. 10. The pharmaceutical composition of claim 1, wherein the ratio (w/w) of albumin to the paclitaxel in the pharmaceutical composition is about 1:1 to about 5:1. 11. The pharmaceutical composition of claim 1, wherein the ratio (w/w) of albumin to the paclitaxel in the pharmaceutical composition is 1:1 to 9:1. 12. The pharmaceutical composition of claim 1, wherein the ratio (w/w) of albumin to the paclitaxel in the pharmaceutical composition is about 9:1.